Gilead Sciences, Inc. (GILD): Capital Expenditures
$563.00M
Year ended 2025-12-31
$609.00M
Trailing 12 months to 2026-06-30
-8.2%
3-year compound annual growth
-2.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $563.00M | +7.6% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $523.00M | -10.6% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $585.00M | -19.6% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $728.00M | +25.7% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $579.00M | -10.9% | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | $650.00M | -21.2% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $825.00M | -10.7% | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | $924.00M | n/a | 2021-02-25, From 2018-01-01 |
| No annual figure between 2013-12-31 and 2018-12-31. | |||
| 2013-12-31 | $134.00M | n/a | 2014-02-25, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $563.00M | +7.6% |
| Amgen Inc (AMGN) | 2025-12-31 | $1.86B | +69.5% |
| Biogen Inc. (BIIB) | 2025-12-31 | $153.80M | +0.1% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $34.00M | -11.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $8.43M | -70.4% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $201.05M | +20.3% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $192.00M | -81.7% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $6.97M | -34.8% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
Compare GILD, AMGN, BIIB, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗